Plain-English translation of NCT06735014 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing whether advanced MRI scans of the brain and spine can detect small changes in ALS disease over short periods of time—even 3 to 6 months. Currently, doctors track ALS using functional tests that may not pick up early changes. This study aims to show that these imaging scans are sensitive enough to become reliable markers of disease progression in future ALS treatment trials.
ALS clinical trials need better ways to measure whether a treatment is working. Current methods may require large groups of patients and long study periods, making trials difficult and expensive. This research could provide a faster, more sensitive way to detect disease changes, which would make future treatment trials smaller, quicker, and more feasible.
You likely qualify if…
You likely don't qualify if…
You would visit one of three study sites where you'll receive MRI scans of your brain and spine. The study will follow you over time with repeat scans and visits, likely over several months, to track any changes. Researchers will also compare your imaging results with other health measurements and blood tests to understand how the imaging changes relate to disease progression.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Sponsor
University of Minnesota
Collaborators
Food and Drug Administration (FDA), Minnesota Office of Higher Education
Enrollment target
~90 participants
Started
September 2024
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Melisa Bailey, MS
University of Minnesota
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.